DK1086702T3 - Præsynaptiske neurotoksiner til behandling af migrænehovedpine - Google Patents

Præsynaptiske neurotoksiner til behandling af migrænehovedpine

Info

Publication number
DK1086702T3
DK1086702T3 DK00204206T DK00204206T DK1086702T3 DK 1086702 T3 DK1086702 T3 DK 1086702T3 DK 00204206 T DK00204206 T DK 00204206T DK 00204206 T DK00204206 T DK 00204206T DK 1086702 T3 DK1086702 T3 DK 1086702T3
Authority
DK
Denmark
Prior art keywords
treatment
migraine headaches
presynaptic neurotoxins
presynaptic
mammal
Prior art date
Application number
DK00204206T
Other languages
Danish (da)
English (en)
Inventor
William J Binder
Original Assignee
William J Binder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1086702(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by William J Binder filed Critical William J Binder
Application granted granted Critical
Publication of DK1086702T3 publication Critical patent/DK1086702T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
DK00204206T 1994-05-09 1995-05-02 Præsynaptiske neurotoksiner til behandling af migrænehovedpine DK1086702T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24097394A 1994-05-09 1994-05-09
US34333194A 1994-11-21 1994-11-21
EP95918353A EP0758900B1 (fr) 1994-05-09 1995-05-02 Toxine de Botulinum pour la REDUCTION DES CEPHALEES DE LA MIGRAINE

Publications (1)

Publication Number Publication Date
DK1086702T3 true DK1086702T3 (da) 2005-05-23

Family

ID=26933871

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00204206T DK1086702T3 (da) 1994-05-09 1995-05-02 Præsynaptiske neurotoksiner til behandling af migrænehovedpine
DK95918353T DK0758900T3 (da) 1994-05-09 1995-05-02 Botulinumtoksin til reduktion af migræne-hovedpinesmerter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95918353T DK0758900T3 (da) 1994-05-09 1995-05-02 Botulinumtoksin til reduktion af migræne-hovedpinesmerter

Country Status (12)

Country Link
US (1) US5714468A (fr)
EP (2) EP1086702B1 (fr)
JP (1) JP3066079B2 (fr)
AT (2) ATE292977T1 (fr)
AU (1) AU2431995A (fr)
CA (2) CA2190011C (fr)
DE (2) DE69526340T2 (fr)
DK (2) DK1086702T3 (fr)
ES (2) ES2174945T3 (fr)
LU (1) LU92052I2 (fr)
PT (2) PT1086702E (fr)
WO (1) WO1995030431A1 (fr)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP1591129B1 (fr) * 1993-12-28 2010-02-24 Allergan, Inc. Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à la dystonie cervicale
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
JP2002501033A (ja) 1998-01-26 2002-01-15 ユニバーシティー オブ マサチューセッツ Ａ型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法
US7537773B1 (en) 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
US6139545A (en) * 1998-09-09 2000-10-31 Vidaderm Systems and methods for ablating discrete motor nerve regions
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU3952300A (en) * 1999-04-16 2000-11-02 Brian Jeffrey Freund Method to reduce hair loss and stimulate hair regrowth
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
WO2001058472A2 (fr) * 2000-02-08 2001-08-16 Allergan, Inc. Compositions pharmaceutiques a base de toxine botulique
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6753315B2 (en) 2000-02-24 2004-06-22 Brown University Research Foundation α-bungarotoxin molecules and uses thereof
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
IL153734A0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7223577B2 (en) * 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
WO2003047589A1 (fr) * 2001-11-15 2003-06-12 Micro Algae Corporation Compositions pharmaceutiques contenant des 3,4-propinoperhydropurines et utilisations de celles-ci pour bloquer la transmission neuronale
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
WO2003073994A2 (fr) * 2002-03-01 2003-09-12 Elan Pharmaceuticals, Inc. Methodes de traitement de syndromes nerveux compressifs
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
MXPA05003936A (es) * 2002-10-15 2005-06-17 Allergan Inc Terapias y procedimientos odontologicos con toxina botulinica.
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
WO2004076634A2 (fr) * 2003-02-24 2004-09-10 Ira Sanders Translocation par membrane cellulaire d'inhibiteurs snare régulés, compositions associées et procédés de traitement de pathologies
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
CA2518157C (fr) * 2003-03-06 2018-09-04 Botulinum Toxin Research Associates, Inc. Traitement des cephalees et des douleurs faciales chroniques associees a la sinusite au moyen de toxine botulinique
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
WO2004084839A2 (fr) * 2003-03-24 2004-10-07 Cady Roger K Methode et article pour le traitement de troubles associes a des neurones sensoriels par une application transdermique de toxine botulinique
WO2004093949A1 (fr) 2003-04-16 2004-11-04 Allergan, Inc. Dispositif d'injection aspiration a volume controle
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
ES2568953T3 (es) * 2004-05-07 2016-05-05 Phytotox Limited Administración transdérmica de ficotoxinas
US20080021051A1 (en) * 2004-05-07 2008-01-24 Phytotox Limited Phycotoxins and Uses Thereof
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7811584B2 (en) 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
CA2572865C (fr) 2004-07-09 2017-07-25 Robert Sabin Compositions pour le traitement de maladies mammaliennes et leurs procedes d'utilisation
US20070258900A1 (en) * 2004-07-20 2007-11-08 Joseph Francis Blood Flow Assessment of Clostridial Toxin Applications
US8173797B2 (en) * 2004-07-21 2012-05-08 Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
WO2006096163A1 (fr) 2005-03-03 2006-09-14 Allergan, Inc. Systeme exempt de produits animaux et procede de purification d'une toxine botulinique
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
US7731411B2 (en) * 2005-04-04 2010-06-08 Schlumberger Technology Corporation Circulating fluid system for powder fluidization and method of performing same
WO2006122123A2 (fr) * 2005-05-09 2006-11-16 Levin Bruce H Procedes de soulagement de troubles et de leurs douleurs associees
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
DE102005058639A1 (de) * 2005-12-07 2007-07-26 Armin Maurer Behandlung von Trichodynie und anschwellender Arteria temporalis superficialis
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
ES2520765T3 (es) 2007-02-15 2014-11-11 Allergan, Inc. Uso de toxina botulínica para el tratamiento de hiperhidrosis
AU2008316988A1 (en) * 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
US8512715B2 (en) 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9204925B2 (en) 2008-08-14 2015-12-08 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9066851B2 (en) 2008-12-04 2015-06-30 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CA2774951C (fr) 2009-09-24 2014-12-16 Allergan, Inc. Methode de traitement de l'osteoporose avec une neurotoxine
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
AU2011315962B2 (en) 2010-10-14 2016-06-02 Allergan, Inc. Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
WO2012103415A1 (fr) 2011-01-28 2012-08-02 Allergan, Inc. Schéma posologique destiné à traiter des troubles multiples par le biais de toxines botuliniques
US10111938B2 (en) 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US9764009B2 (en) 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
KR20140054028A (ko) 2011-07-08 2014-05-08 알러간, 인코포레이티드 자율신경계 장애의 치료방법
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
RU2578475C2 (ru) 2011-07-14 2016-03-27 Аллерган, Инк. Способы лечения недержания, связанного с половой активностью
CN103702681A (zh) 2011-07-20 2014-04-02 阿勒根公司 用于治疗脂肪沉积的方法
EP3257526B1 (fr) 2012-03-12 2019-10-16 William J. Binder Traitement de la migraine par des neurotoxines présynaptiques
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
US8491917B1 (en) 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
EP2649983A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (II)
CA2869599C (fr) 2012-04-13 2021-07-27 Lubrizol Advanced Materials, Inc. Composes inhibant l'exocytose neuronale (ii)
EP2649985A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (III)
EP2649984A1 (fr) 2012-04-13 2013-10-16 Lipotec, S.A. Composés qui inhibent l'exocytosis neuronale
KR102060355B1 (ko) 2012-05-30 2019-12-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 가공된 보툴리눔 신경독소
WO2014066916A2 (fr) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions et procédés pour le traitement sûr de la rhinite
WO2014078724A1 (fr) 2012-11-16 2014-05-22 Finzi Eric Traitement d'un état de stress post-traumatique à l'aide de la toxine a botulique
BR112015024221A2 (pt) 2013-03-22 2017-07-18 Lipotec Sa exopolissacarídeo, uso do exopolissacarídeio, e, composição cosmética ou dermofarmacêutica
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
ES2895853T3 (es) 2015-03-26 2022-02-22 Harvard College Neurotoxina botulínica modificada
US11104891B2 (en) 2016-06-08 2021-08-31 Children's Medical Center Corporation Engineered botulinum neurotoxins
IL298102A (en) 2016-07-08 2023-01-01 Childrens Medical Center A new botulinum neurotoxin and its derivatives
WO2018039506A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Neurotoxine botulique manipulée
WO2018038301A1 (fr) 2016-08-26 2018-03-01 Hugel Inc. Formulation liquide stabilisée de toxine botulique et procédé pour sa préparation
IL308091A (en) 2016-09-13 2023-12-01 Allergan Inc Stabilized Clostridium toxin preparations without protein
JP2021500871A (ja) 2017-09-29 2021-01-14 ザ チルドレンズ メディカル センター コーポレーション ニューロトキシン様トキシンおよびそれらの使用
EP3470054B1 (fr) 2017-10-11 2023-09-20 Hugel Inc. Techniques de formulation de microstructure pour toxine botulinique
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
EP3825689A3 (fr) 2018-11-29 2021-09-15 Hugel Inc. Procédé basé sur des cellules permettant de déterminer une activité de toxine botulinique
US11752201B2 (en) 2019-01-07 2023-09-12 Babak Azizzadeh Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels
MX2022002489A (es) 2019-08-30 2022-03-22 Aeon Biopharma Inc Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
TW202136518A (zh) 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2153781A1 (fr) * 1993-01-15 1994-07-21 Gary E. Borodic Methode pour traiter la douleur myofaciale
EP1591129B1 (fr) * 1993-12-28 2010-02-24 Allergan, Inc. Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à la dystonie cervicale
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin

Also Published As

Publication number Publication date
PT1086702E (pt) 2005-08-31
DE69526340T2 (de) 2002-11-14
PT758900E (pt) 2002-09-30
CA2190011A1 (fr) 1995-11-16
LU92052I2 (fr) 2013-04-03
ES2238969T3 (es) 2005-09-16
ATE215832T1 (de) 2002-04-15
DE69534150D1 (de) 2005-05-19
EP1086702A3 (fr) 2001-04-04
US5714468A (en) 1998-02-03
ATE292977T1 (de) 2005-04-15
EP1086702A2 (fr) 2001-03-28
CA2190011C (fr) 2000-09-26
EP0758900A1 (fr) 1997-02-26
EP0758900A4 (fr) 1997-05-21
JP3066079B2 (ja) 2000-07-17
DE69526340D1 (de) 2002-05-16
EP0758900B1 (fr) 2002-04-10
DE69534150T2 (de) 2006-02-16
DK0758900T3 (da) 2002-07-29
CA2312047A1 (fr) 1995-11-16
WO1995030431A1 (fr) 1995-11-16
AU2431995A (en) 1995-11-29
EP1086702B1 (fr) 2005-04-13
ES2174945T3 (es) 2002-11-16
JPH10500406A (ja) 1998-01-13

Similar Documents

Publication Publication Date Title
DK1086702T3 (da) Præsynaptiske neurotoksiner til behandling af migrænehovedpine
NO905322D0 (no) Aminosyrederivater.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
FI920450A0 (fi) Metoder och kompositioner foer foerhindrande av symtomer av sepsis.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
DE69213935T2 (de) Neue heterocyclische carbonsäuren
SE0004101D0 (sv) New use
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ES2113938T3 (es) Isomeros opticos de 7-(3-(1,1-dialquilmetil-1-amino)-1-pirrolidinil)-quinolonas y naftiridonas utilizados como agentes antibacterianos.
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
PT1181012E (pt) Valproato intravenoso para tratamento de enxaqueca aguda
EE200100026A (et) Oksasolidinoonid silmahaiguste raviks
AU4132397A (en) Therapeutic formulations containing venom or venom anti-serum either lone or in combination for the therapeutic prophylaxis and therapy of neoplasms
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
FI97884B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-dihydroksi-2,5-dihydrofuranonien valmistamiseksi
DK0872239T3 (da) Anvendelse af olanzapin til fremstilling af et lægemiddel til behandling af cerebral fokal iskæmi
MX9304056A (es) Compuestos para el tratamiento de padecimientos neoplasticos.
MX9102289A (es) Isomeros opticos de 7-]3-(1-1-dialquilmetil-1-lamino)-1-pirrolidinil)-quinolonas y naftiridonas, como agentes antibacterianos.
MX9204845A (es) Combinaciones de compuestos de cloruro de amonio ymetodo para el tratamiento de infecciones virales.